INTRODUCTION
with activity against extended-spectrum cephalosporins.
Sequencing of the encoding genes revealed that most ESBLs described in the 1980s were progenies of the above-mentioned TEM and SHV enzymes. Amino acid sequences of TEM and SHV enzymes are listed on the website dedicated to the nomenclature of β -lactamases hosted by George Jacoby and Karen Bush [4] together with other enzymes (e.g., OXA, CTX-M, CMY, IMP, VIM, and KPC).
In 1989, a clinical isolate of E. coli that produced a non-TEM, non-SHV ESBL was reported. The enzyme was designated CTX-M-1, indicating its preferential hydrolytic activity against cefotaxime [5] . Although spread of CTX-Mproducing isolates appeared to be limited to specific areas in the world during the 1990s, this situation has changed during the past decade. Recent epidemiological studies of ESBL-producing bacteria demonstrated a dramatic increase in the prevalence of CTX-M enzymes globally [6] [7] [8] .
DEFINITION OF ESBL
β -Lactamases are commonly classified according to two general schemes: the Ambler molecular classification and the Bush-Jacoby-Medeiros functional classification [9, 10] .
The Ambler scheme classifies β -lactamases into four classes according to the protein homology of enzymes. β -Lactamases of class A, C, and D are serine β -lactamase and class B enzymes are metallo-β -lactamases. The Bush-Jacoby-Medeiros functional scheme is based on functional properties of enzymes, i.e., the substrate and inhibitor profiles.
The term 'extended-spectrum β -lactamses'was originally applied to the TEM and SHV derivatives that can hydrolyze oxyimino-cephalosporins, and these enzymes were classified as group 2be with the Bush-Jacoby-Medeiros functional scheme. The 2be designation consists of '2b'denoting that the enzyme is derived from a 2b enzyme (e.g., SHV-1, TEM-1, and TEM-2) and 'e'representing the 'extended spectrum of activity' . The definition of extended spectrum of activity is to have a hydrolytic activity against oxyimino-cephalosporins or aztreonam at more than 10% of that against benzylpenicillin. 2be enzymes cannot hydrolyze cephamycins or carbapenems efficiently and are inhibited by β -lactamase inhibitors such as clavulanate.
TEM-ESBLs and SHV-ESBLs belong to class A in the Ambler scheme.
Discovery of several novel enzymes have blurred the original definition of ESBLs [11] . First, several β -lactamses with activity similar to those of TEM and SHV ESBLs, albeit with different origin, have been reported (e.g., CTX-M).
Second, some TEM mutants, e.g., TEM-7, and TEM-12, have only slightly increased hydrolytic activity against oxyimino-cephalosporins and do not meet the strict definition of ESBL mentioned above. Third, several enzymes not classified into class A have a hydrolytic profile similar to that of 2be enzymes. For example, some OXA derivatives have broader hydrolytic profiles than their parent enzymes and can confer resistance to oxyimino-cephalosporins.
Typical class C enzymes can confer resistance to oxyimino-cephalosporins if they are hyperproduced as a consequence of mutational derepression [12] or are expressed constitutively on plasmid [13] . Class C enzymes are resistant to the inhibition by β -lactamase inhibitors and are not deemed a member of ESBLs. Recently, AmpC mutants with increased hydrolytic activity against cefepime and cefpirome (extended-spectrum cephalosporinases) have been reported.
Although it has been determined that such mutants were mainly located on bacterial chromosome [14] [15] [16] , two plasmid-mediated extended-spectrum cephalosporinases, CMY-19 [17] and CMY-10 [18] , have been reported. Some specialists may insist on regarding such enzymes as ESBLs because of their wide spectrum of activity.
Class A β -lactamases that can hydrolyze carbapenems have been reported (e.g., KPC, NMC/IMI, and SME) [19] .
Most of these enzymes also hydrolyze oxyimino-cephalosporins. From the clinical point of view, it is not practical to categorize these enzymes as ESBLs because carbapenems are regarded as the drug of choice for ESBL-producing organisms. GES enzymes pose a more difficult problem on this matter. GES-1 possesses hydrolytic activity similar to the classic class A ESBLs, is inhibited by β -lactamase inhibitors [20] , and is generally classified into ESBL.
However, some of the GES variants, such as GES-2 and 4, also have hydrolytic activity against carbapenems [21, 22] .
SHV
SHV-1 is a β -lactamase with activity against penicillins and narrow-spectrum cephalosporins such as cephalothin and cephaloridine [23] . Although blaSHV-1 and related genes are integrated into the bacterial chromosome in most isolates of K. pneumoniae [1, 24] , SHV-1 is also common as a plasmid-mediated β -lactamase among gram-negative bacteria.
The first plasmid-mediated resistance mechanism for oxyimino-cephalosporins was demonstrated in clinical isolates of K. pneumoniae, Klebsiella ozaenae, and S. marcescens in 1983 [3] . The new enzyme was designated SHV-2 because of a significant homology between the gene encoding new enzyme and blaSHV-1 [25] . Sequencing of the structural genes showed that the difference between two enzymes was only one amino-acid substitution of Gly238Ser.
A number of SHV variants with ESBL activity have been described thereafter [26] . Most of them have a Gly238Ser substitution in common. In addition, a number of variants related to SHV-5 also have a Glu240Lys substitution. Ser-238 is crucial for cefotaxime hydrolysis whereas additional Glu240Lys substitution increases the hydrolytic activity against ceftazidime [27] .
It was suggested that blaSHV originated from the chromosome of K. pneumoniae and an IS26 element played a role in the mobilization of blaSHV to plasmid [28] . Indeed, some reports illustrated the presence of blaSHV-5 between two IS26 elements together with the sequence identical to part of the K. pneumoniae chromosome [29, 30] .
TEM
TEM-1, first reported in 1965 from an Escherichia coli isolate, has substrate and inhibition profiles similar to those of SHV-1 [2] . Ampicillin resistance in clinical isolates of E.
coli is due to the production of TEM-1 in most instances.
TEM-2 has a single amino acid substitution Gln39Lys from TEM-1 and has an almost identical hydrolytic profile with TEM-1. It only differs from TEM-1 by having a different isoelectric point [31] .
In 1987, K. pneumoniae isolates exhibiting resistance to multiple antibiotics including oxyimino-cephalosporins were detected and the β -lactamase produced by these isolates was designated as CTX-1 referring to its hydrolytic activity against cefotaxime [32] . Sequencing of the gene encoding the enzyme revealed that the enzyme was related to TEM-2 and differed by two amino acids from its parent enzyme: Lys for Glu at position 102 and Ser for Gly at position of 236 [33] . Since the first TEM variant was reported, more than 150 TEM-type β -lactamases have been described.
Most of these enzymes have ESBL activity, whereas other TEM variants reveal the characteristics of inhibitor-resistant β -lactamases [34] . Mutations in several key amino acid residues (e.g., Glu104Lys, Arg164Ser, Gly238Ser, and Glu- 
CTX-M
In 1989, a clinical E. coli isolate that produced a non-TEM, non-SHV ESBL was recovered and the enzyme was designated CTX-M-1, denoting its hydrolytic activity against cefotaxime [36] . The amino acid sequence of β -lactamase from clinical E. coli isolate MEN exhibiting resistance phenotype similar to the E. coli isolate producing CTX-M-1
Extended-spectrum β -Lactamases: Implications for the Clinical Laboratory and Therapyenzyme was determined and the enzyme was designated MEN-1 in 1992 [37] . In the same year, a new plasmid-mediated cefotaximase, designated CTX-M-2, with an isoelectric point different from that of CTX-M-1, was described from multidrug-resistant Salmonella enterica serovar Typhimurium [38] . In 1995, Ishii et al. [39] reported a novel enzyme, Toho-1 (renamed as CTX-M-44 later), which was highly homologous to MEN-1. In the following year, nucleotide sequencing studies concluded that the deduced amino acid sequence of CTX-M-1 was identical to the reported sequence of MEN-1, and the amino acid sequence of CTX-M-2 was 84% identical to that of CTX-M-1 [40] .
In addition, Toho-1 was found to be more closely related to CTX-M-2 than to CTX-M-1. To date, more than 80 CTX-M enzymes have been described [4] . boring genes by one-ended transposition mechanism. A recent in vitro study showed that the mobilization of bla CTX-M-2 from K. ascorbata to E. coli was achievable in the presence of ISEcp1 [45] . Genes encoding the CTX-M-2 subgroup and the CTX-M-9 subgroup have also been observed within ISCR1 associated with class 1 integron. It has been shown that both ISEcp1 and ISCR1 provide promoter sequences for high-level expression of CTX-M enzymes [46, 47] . Additionally, a recent study demonstrated the presence of a phage-related sequence immediately upstream of blaCTX-M-10 in several CTX-M-10-producing isolates [48] , suggesting that bacteriophage might be involved in an acquisition of blaCTX-M-10.
Organisms harboring CTX-M enzymes are resistant to cefotaxime, whereas they often appear to be susceptible to ceftazidime in vitro. Additionally, most CTX-M enzymes hydrolyze cefepime effectively and MIC values of cefepime for bacteria producing CTX-M enzymes tend to be higher than those for bacteria producing other types of ESBLs [49] .
Analysis of the crystal structure of CTX-M enzymes has revealed that the active sites of CTX-M enzymes resemble those of narrow-spectrum TEM and SHV enzymes (e.g., TEM-1, SHV-1) and are not large enough to recognize ceftazidime, which is larger than cefotaxime [50, 51] . However, substitution of several amino acids improves the activity of CTX-M enzyme against ceftazidime. Substitutions of Asp240 and Pro167 are known to lead to such alteration in a hydrolytic profile. Asp240Gly substitution appears to increase the flexibility of B3 β -strand allowing an increase in the activity against ceftazidime [50] . Mutation at Pro167 in the omega-loop modifies the interaction between β -lactams and the binding sites as well [52] . 
GES
GES-1 was initially described in a K. pneumoniae isolate from a neonatal patient just transferred to France from French Guiana [20] . GES-1 has hydrolytic activity against penicillins and extended-spectrum cephalosporins, but not against cephamycins or carbapenems, and is inhibited by β -lactamase inhibitors. These enzymatic properties resemble those of other class A ESBLs; thus, GES-1 was recognized as a member of ESBLs.
However, a Gly170 substitution inside the omega-loop appears to alter the substrate profile of the enzyme. GES-2, which has Gly170Asn substitution compared with GES-1, has an increased activity against imipenem and decreased activity against oxyimino-cephalosporins [21] . In addition, GES-2 is only weakly inhibited by β -lactamase inhibitors.
GES-4, which has a Gly170Ser substitution compared with GES-3, is also capable of hydrolyzing carbapenems and weakly inhibited by β -lactamase inhibitors. Furthermore, GES-4 extends its hydrolytic activity towards cephamycins [22] . 
OXA

Other ESBLs
A number of other groups of β -lactamases capable of hydrolyzing extended-spectrum cephalosporins have been reported. VEB, PER, BEL, BES, TLA, SFO, and IBC are examples of such enzymes and details of these enzymes are reviewed elsewhere [56] .
DETECTION OF ESBLs IN CLINICAL LABORATORIES
Detection of organisms harboring ESBLs provides clinicians with helpful information. Treatment of infections
caused by ESBL-producing organisms with extended-spectrum cephalosporins or aztreonam may result in treatment failure even when the causative organisms appear to be susceptible to these antimicrobial agents by routine susceptibility testing [57, 58] . In addition, patients colonized or infected with ESBL-producing organism should be placed under contact precautions to avoid hospital transmission [59] . μ g/mL is the susceptible range for Enterobacteriaceae.
In the Phenotypic Confirmatory Test, susceptibilities to cefotaxime and ceftazidime alone, and those with clavulanate are compared using disk diffusion or broth dilution method (Fig. 1) . If the susceptibility of either antibiotic tested increases significantly (a ≥5 mm increase in a zone diameter or a ≥3 two-fold decrease in an MIC) in the presence of clavulanate, the result is interpreted as confirmatory of ESBL production. It is important to perform confirmatory tests using both ceftazidime and cefotaxime to improve the sensitivity of the test. A report suggests that the use of ceftazidime alone leads to oversight of production of CTX-M type ESBLs [63] .
DOUBLE DISK SYNERGY TEST
Double disk synergy test (DDST) was the first proposed testing method for phenotypic detection of ESBL-producing organisms [64] . DDST is performed on an agar plate with a disk containing cefotaxime (30 μ g) and a disk con- If the result of DDST is negative despite the high suspicion of ESBL production, adjustment of disk spacing is advised.
Application of the disks closer to each other significantly improves the sensitivity of DDST [65, 66] . In addition, the use of cefepime instead of third-generation cephalosporins improves the sensitivity of DDST when it is applied for AmpCproducing Enterobacteriaceae (e.g., Enterobacter spp, K.
pneumoniae producing plasmid-mediated AmpC β -lactamase) [66] . This phenomenon is plausible because cefepime is stable against hydrolysis by most AmpC β -lactamases.
ETEST FOR ESBLs
The Etest ESBL TZ/TZL (AB biodisk, Solna, Sweden) is a Fig. 1 . Positive CLSI recommended method for ESBL producing strains. The inhibition zone around the CTX/CVA disk is apparently larger than that around the CTX disk, indicating ESBL production. Comparable result is obtained with CAZ disk and CAZ/ CVA disk. Note that the inhibition zone diameter around the CAZ disk is within the susceptible range (≥18 mm). Adherence to the protocol and the use of both CTX and CAZ disks are crucial for the highly sensitive detection of ESBL production. Abbreviations: CTX, cefotaxime; CAZ, ceftazidime; CVA, clavulanic acid. The presence of "phantom zone"below the CTL, TZL, or PML gradient and ellipse deformation at the tapered end also indicate ESBL production (Fig. 2) . When mutant colonies are observed in the inhibition zone, the MIC value should be determined by reading the drug concentration at which mutant colonies are completely inhibited. If these rules are not followed, a high rate of discrepancy between the MICs obtained by experts and those by laboratory technicians may occur [68] . Several studies have evaluated the performance of these automated systems in detecting ESBL-producing organisms [68] [69] [70] [71] [72] [73] . These studies employed a variety of study designs and showed variable results. For example, several studies used only E. coli and Klebsiella spp. as test organisms, whereas others included species with chromosomal AmpC β -lactamases production.
AUTOMATED METHOD
VITEK
DETECTION METHOD WITH BORONIC ACID
Boronic acid is known to inhibit the activity of AmpC β -lactamases, and several studies have reported its utility in the detection of organisms producing both AmpC β -lactamase and ESBL. Addition of 3-aminophenyl boronic acid on antibiotic-containing disks (cefotaxime/ceftazidime with or without clavulanate) has been reported to potentiate the sensitivity and specificity of the combination disk method when this method is applied to organisms with chromosomal [74] or plasmid-mediated [75] AmpC production.
TREATMENT OF INFECTIONS CAUSED BY ESBL-PRODUCING ORGANISMS
Antibiotic choices for infections caused by ESBL-producing organisms are limited [57, 76] . Treatment of these infections with cephalosporins (except for cephamycins) has
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In the past decade CTX-M-type ESBLs have become prevalent globally and their distribution involves not only healthcare environments but also the community. Community-acquired infections due to ESBL-producing organisms pose a serious challenge to clinicians in choosing appropriate empiric therapy. The incidence of such infections is currently low, but we have to pay attention to the trend.
